# A Study of LY3002813 in Participants With Memory Damage Due to Alzheimer's Disease (AD) or AD

> **NCT02624778** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 61 (actual)

## Conditions studied

- Alzheimer Disease

## Interventions

- **BIOLOGICAL:** LY3002813
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02624778
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12-22
- **Primary completion:** 2019-08-28
- **Final completion:** 2019-08-28
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2024-10-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02624778

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02624778, "A Study of LY3002813 in Participants With Memory Damage Due to Alzheimer's Disease (AD) or AD". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02624778. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*